Healthy Non-Obese Adults (2010-2012)
- Develop better predictive equations for BMR in healthy Chinese adults
- Evaluate factors that may influence BMR.
Definitions
- Steady state: VO2and CO2measurements obtained every 30-secs until equilibrium achieved for at least 5 to 6 consecutive minutes
- Harris-Benedict equation: Cited 1918 study
- Ideal body weight: Cited Huang 1992 for Chinese persons
- Body fat: Siri’s equation, 1961
- Body Surface Area (BSA) equation: used formula derived from Dubois and Dubois
- Body Cell Mass (BCM) equation: Used Moore equation
- Fat-free mass (FFM): Body weight (1-%body fat).
- Understand and give written consent
- Healthy
- Normal weight for Chinese persons (based on equations derived by Huang et al for Chinese persons).
- Refusal to consent
- Hx of current illnesses
- Recent weight loss
- Endocrine disorders
- Pharmacologic therapy
- Hormonal treatment
- Extremely underweight (<80% IBW) or obese (120% IBW).
Recruitment
Procedures not described
Design
Cross-sectional study
Subjects stratified on basis of gender and age (20-29, 30-39, 40-49, 50-59, 60+ years)
Blinding used
Not applicable
Intervention
Not applicable
Statistical Analysis
- Student's T-test used to assess differences between men and women
- Pearson correlation coefficients and linear regression analyses used to evaluate relationships between measured BMR and age, weight, height, percentage ideal body weight, percent body fat, fat-free mass, body surface area and body cell mass results expressed as mean±standard deviation (SD)
- Cross-validation study: Sample was randomly divided into two groups for development and cross-validation of predictive equations; there were no differences in body composition parameters between each sample.
Timing of measurements
One measurement time
Dependent variables
- Measured BMR: Indirect calorimetry [(VO2, liters per minute), VCO2 (liters per minute; ml/kg per minute)].
- C type: Metabolic cart with a canopy system
- Rest before measure: “Relaxed supine position”
- Fasting length: 12 hours; Measured between 8-10 a.m.
- Exercise conditioning 24 prior to test: Refrain 12 hours before test
- Smoking: Refrain one hour before test
- Room temp: Not reported
- No. of measures were they repeated? O2 and CO2 taken at 30 second intervals until a steady-state was achieved and maintained for at least five to six consecutive minutes
- Steady state: VO2 and CO2 measurements obtained every 30-seconds until equilibrium achieved for at least five to six consecutive minutes
- Coefficient of variation? None reported
- Equipment of Calibration: None reported
- Training of measurer? Dietitians trained to use a standardized protocol
- Subject training of measuring process? None reported
- Sleep at the facility: Not reported
- Monitored heart rate? None reported
- Body temperature? None reported.
Independent variables
- Predicted REE using HB, Mifflin, Owen (men), Owen(women), Kleiber, Cunningham
- Harris-Benedict equation: Cited 1918 study
- Height: Method not reported
- Weight: Method not reported
- Body mass index (BMI: kg/m2
- Ideal body weight: based on Huang, 1992 for Chinese persons
- Body composition (body fat and fat free mass): sum of skinfolds (biceps, triceps, subscapular, suprailiac) and bioelectrical impednace analysis, resistance and reactance
- Body fat: Siri’s equation, 1961
- Fat free mass (FFM): body weight (1% body fat)
- Body Surface Area (BSA) equation: Formula derived from Dubois and Dubois
- Body Cell Mass (BCM) equation: Moore equations for males and females.
Control variables
Age and gender: Sample stratified
- Initial N: Not given
- Attrition (final N): N=223 Chinese adults (N=102 males; N=121 females)
- Age: Mean age: 43.8±14.3 years; range: 20-78 years
- Ethnicity: Chinese
- Anthropometrics:
Men N=102 Mean±SD | Women N=121 Mean ±SD | |
Weight, kg | 63.5±7.6 | 52.9±5.0* |
Height, cm | 167.5±5.3 | 157±4.0* |
BMI | 22.6±2.4 | 21.5±2.2 |
BFS, percent | 15.2±4.4 | 28.6±4.2* |
BFB, percent | 15.7±3.7 | 27.6±3.7*# |
FFMS, kg | 53.7±5.2 | 37.6±2.7* |
FFMB, kg | 53.4±6.1 | 38.2±2.8* |
BCM, kg | 25.8±3.2 | 17.9±1.3* |
BSA, m2 | 1.72±0.11 | 1.51±0.08* |
%IBW | 103.7±10.9 | 101.3±9.8 |
- BFS: Body fat measured by BIA; BFB- Body fat measured by bioelectrical impedance analysis; FFMS-fat-free mass measured by skinfold thicknesses; FFMB- fat-free mass measured by BIA, BCM-body cell mass; BSA- body surface area
- * Significantly different from men at P=0.0001
- # Significantly different from BFS at P=0.02.
- Location: Taipei, Taiwan.
Pearson Correlation Coefficients between:
- BMR and weight: 0.77
- BMR and height: 0.73
- BMR and age: -0.25
- BMR and percent IBW: 0.33
- BMR and BFS: -027
- BMR and BFB: -0.34
- BMR and FFMS: 0.84
- BMR and FFMB: 0.86
- BMR and BSA: 0.80
- BMR and BCM: 0.89.
BMR best correlated with body cell mass (BCM) and BCM correlated best with fat-free mass by BIA (R=0.94). There was a negative correlation between BCM and age (-0.28).
BMR adjusted for body composition and body surface area
Male N=102 | Female N=121* | |
BMR/weight kcal/kg |
22±2 | 20±2* |
BMR/FFM kcal/kg |
26±2 | 28±3* |
BMR/BCM kcal/kg |
54±4 | 59±5* |
BMR/BSA kcal/m2 | 799±69 | 700±76 |
* P=0.0001
Clinical: Resting energy expenditure
Male Mean±SD | Female Mean±SD | |
VO2 (mL/min) | 197±23 | 153±16* |
VCO2 (mL/min) | 175±21 | 134±16* |
RQ | 0.89±0.05 | 0.88±0.05 |
- P=0.0001
Differences between measured and predicted RMR in males and females comparison measured BMR and estimate BMR (i.e., total sample) by different predictive equations
[Taken from Liu HY, Lu YF, Chen WJ. Validity of predictive equations for the calculation of basal metabolic rate in healthy Chinese adults. Chinese Nutr Soc. 1994; 19 (2): 141-150.]
Kcal/day (±SD) | (Percent±SD) | |
Males, N=102; Females, N=121 |
||
Measured | 1,202±207 | |
Harris & Benedict |
1,3?5±170 | (114±11%) |
Mifflin |
1,288±198 | (108±9%) |
Owen |
1,336±185 | (112±11%) |
Differences between measured and predicted RMR in males and females
Kcal per day (±SD) | (Percent±SD) | |
Males, N=102 |
||
Measured |
1,372±175 | |
Harris & Benedict |
1,481±167 | (108±8%) |
Mifflin |
1,470±131 | (108±8%) |
Owen | 1,527±77 | (112±11%) |
Females, N=121 |
||
Measured |
1,058±113 | |
Harris & Benedict |
1,258±70 | (119±11%) |
Mifflin |
1,135±82 | (108±10%) |
Owen | 1,176±36 | (112±11%) |
Developing predictive equations
The men and women in the two samples (validation and cross-validation) were comparable in age, anthropometric measurements (height and weight), body composition (including percent body fat, fat-free mass and body cell mass) and body surface area.
The mean difference, r and P-value for paired T-test results between predicted BMR (X-var) and measured BMR (Y-var) using cross-validation sample (N=104):
Mean difference (kcal per day) |
r | P-value | |
HB |
158±111 | 0.84 | 0.0001 |
Cunningham (Uses FFM variable) |
278±111 | 0.85 | 0.0001 |
Owen |
137±114 | 0.84 | 0.0001 |
Mifflin |
92±97 | 0.88 | 0.0001 |
Kleiber |
262±142 | 0.73 | 0.0001 |
Mifflin |
117 | 0.44 | 0.0001 |
- All of the available predictive equations overestimated BMR in healthy Chinese adults (P=0.0001)
The mean difference, r and P-value for paired T-test results between predicted BMR (X-var) and measured BMR (Y-var) in cross-validation sample (N=104)
Mean difference (kcal per day) |
r | P-value | |
C3 |
7±96 | 0.89 | 0.4497 |
C5 |
6±100 | 0.88 | 0.5630 |
C6 |
5±98 | 0.88 | 0.6294 |
C7 |
7±101 | 0.87 | 0.5078 |
C8 | 7±101 | 0.87 | 0.5078 |
- No significant differences were observed between measured BMR and predicted values estimated by the nine equations developed in this study
[NOTE: The four equations above are discussed due to availability of obtaining the factors needed.]
- The BMR was estimated in 10 randomly selected subjects from the cross-validation study using Mifflin et al equation and equation 8
- Significant differences were observed between BMR estimated by Mifflin and measured BMR (P=0.0001). No significant differences were observed between measured BMR and BMR estimated by equation 8.
As stated by the author in body of report:
- In our study, women had a lower metabolic rate than men because of a relatively smaller amount of body cell mass; the result of smaller skeletal muscle mass in tandem with greater fat mass.
- The major difference between men and women was the difference in amount of skeletal muscle mass
- Previous findings suggest resting energy expenditure correlated most highly with fat-free mass, which correlated highly with weight and height. Our results agree that accurate determination of height and weight, not calorimetry or assessment of body composition are needed to provide a base for estimating daily energy expenditure of individual mean and women.
- Fat-free mass was the best single predictor of BMR and could explain 75% of the variance observed among people... the same r2 value was obtained when body weight and body height were used to substitute fat-free mass for predicting BMR. The use of four variables-body weight, body height, age and sex resulted in an r2 value of 0.81. 81% of the variance in BMR among persons was accounted for by the covariates of weight, height, age and sex.
- A significant degree of overestimation was still observed in predicting BMR in Chinese adults using the Mifflin et al equations (P=0.0001)
- We do not know if predictive equations overestimated BMR for Chinese adults is the result of ethnic differences or other factors such as climate and lifestyle
- We recommend these [our] equations for clinical use in healthy Chinese adults who are within normal limits for body weight.
Government: | Dept. of Health-Republic of China |
Strengths
Selected an important ethnic group within a healthy population.
Generalizability/Weaknesses
- Large study population represented and stratified by age
- Cross-validated equations on separate stratified sample
- Study weaknesses include:
- No subject training prior to measurement; did not sleep over at facility where measurement being taken-hence definition of “BMR” is most likely “Resting metabolic rate”
- Room temperature not reported
- Sample represents Chinese adults living in Taipei, Taiwan, Republic of China; Hence, considering lifestyle differences-limited generalizability to US-residing Chinese population.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | ??? | |
4. | Was method of handling withdrawals described? | ??? | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | N/A | |
5. | Was blinding used to prevent introduction of bias? | N/A | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | No | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | No | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | N/A | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | N/A | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | No | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | No | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |